Back to School: How biopharma can reboot drug development. Access exclusive analysis here

ONO-4641: Phase II data

The double-blind, international Phase II DreaMS trial in 407 patients aged 18-55 with RRMS showed that once-daily 0.05, 0.1 and 0.15 mg

Read the full 221 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE